Zacks Investment Research lowered shares of Fresenius Medical Care Corporation (NYSE:FMS) from a hold rating to a sell rating in a research note published on Tuesday.

According to Zacks, “Fresenius Medical Care has had a disappointing run on the bourse on a year-to-date basis. The company  ended the second quarter on a mixed note wherein adjusted earnings missed the Zacks Consensus Estimate, while revenues beat the same. Fresenius Medical Care reiterated its full-year guidance. We believe this is in tune with the company’s long-term objective or the ‘Growth Strategy 2020’, wherein it aims to drive revenues to $28 billion by 2020, corresponding to an average annual growth rate of 10%. A wide range of dialysis products, initiatives to attain market traction, solid international foothold, strategic acquisitions and divestments are major catalysts. Fresenius Medical Care has signed an agreement to acquire NxStage Medical for $2 billion. However, a tough regulatory environment, difficulties in boosting the profit margin in foreign legal paradigms and competition in the niche markets are major headwinds.”

Several other analysts also recently weighed in on the company. Royal Bank Of Canada restated a hold rating and set a $44.00 target price on shares of Fresenius Medical Care Corporation in a research note on Wednesday, September 13th. DZ Bank AG restated a buy rating on shares of Fresenius Medical Care Corporation in a research note on Monday, August 7th. BidaskClub downgraded Fresenius Medical Care Corporation from a buy rating to a hold rating in a research note on Monday, July 31st. UBS AG restated a sell rating on shares of Fresenius Medical Care Corporation in a research note on Tuesday, July 4th. Finally, Nord/LB reiterated a buy rating on shares of Fresenius Medical Care Corporation in a research report on Wednesday, June 28th. Two analysts have rated the stock with a sell rating, four have assigned a hold rating and six have issued a buy rating to the company. The stock has a consensus rating of Hold and a consensus price target of $48.67.

Fresenius Medical Care Corporation (NYSE:FMS) traded down 0.22% during midday trading on Tuesday, reaching $48.94. The company’s stock had a trading volume of 77,431 shares. The firm has a market capitalization of $30.04 billion, a PE ratio of 21.00 and a beta of 0.48. The stock has a 50 day moving average of $48.04 and a 200 day moving average of $46.58. Fresenius Medical Care Corporation has a 52 week low of $38.05 and a 52 week high of $50.22.

Fresenius Medical Care Corporation (NYSE:FMS) last announced its earnings results on Tuesday, August 1st. The company reported $0.48 earnings per share for the quarter, missing the consensus estimate of $0.53 by ($0.05). Fresenius Medical Care Corporation had a net margin of 7.06% and a return on equity of 11.57%. The business had revenue of $4.47 billion for the quarter, compared to the consensus estimate of $5.20 billion. During the same quarter in the previous year, the company earned $0.96 EPS. Fresenius Medical Care Corporation’s revenue for the quarter was up 11.1% compared to the same quarter last year. On average, equities research analysts predict that Fresenius Medical Care Corporation will post $2.34 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “Fresenius Medical Care Corporation (FMS) Downgraded by Zacks Investment Research to Sell” was posted by Watch List News and is the sole property of of Watch List News. If you are reading this piece of content on another website, it was copied illegally and republished in violation of United States and international trademark and copyright law. The original version of this piece of content can be read at https://www.watchlistnews.com/fresenius-medical-care-corporation-fms-downgraded-by-zacks-investment-research-to-sell/1615699.html.

Several hedge funds have recently made changes to their positions in the business. Royal Bank of Canada lifted its position in shares of Fresenius Medical Care Corporation by 6.4% in the 2nd quarter. Royal Bank of Canada now owns 501,694 shares of the company’s stock worth $24,248,000 after acquiring an additional 30,119 shares during the period. Goldman Sachs Group Inc. lifted its position in shares of Fresenius Medical Care Corporation by 12.1% in the 2nd quarter. Goldman Sachs Group Inc. now owns 228,756 shares of the company’s stock worth $11,056,000 after acquiring an additional 24,705 shares during the period. YorkBridge Wealth Partners LLC lifted its position in shares of Fresenius Medical Care Corporation by 19.4% in the 2nd quarter. YorkBridge Wealth Partners LLC now owns 4,613 shares of the company’s stock worth $222,000 after acquiring an additional 749 shares during the period. Stifel Financial Corp bought a new stake in shares of Fresenius Medical Care Corporation in the 2nd quarter worth approximately $225,000. Finally, OxFORD Asset Management LLP bought a new stake in shares of Fresenius Medical Care Corporation in the 2nd quarter worth approximately $2,460,000. Institutional investors own 2.61% of the company’s stock.

Fresenius Medical Care Corporation Company Profile

Fresenius Medical Care AG & Co KGaA is a kidney dialysis company. The Company provides dialysis care and related services to persons suffering from end-stage renal disease (ESRD), as well as other healthcare services. The Company’s segments include North America Segment, the Europe, Middle East and Africa (EMEA) Segment, the Asia-Pacific Segment and the Latin America Segment.

Get a free copy of the Zacks research report on Fresenius Medical Care Corporation (FMS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Fresenius Medical Care Corporation (NYSE:FMS)

Receive News & Ratings for Fresenius Medical Care Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius Medical Care Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.